Crohn's Disease Forum » Forum Wiki » Vedolizumab


Vedolizumab, an investigational drug also called MLN0002, is a new anti-adhesion form biologic drug which is currently in Phase III Clinical Trials to to treat IBD. Anti-adhesion drugs operate differently to traditional TNFα drugs, but use the similar Biologic Antibody Based.

Vedolizumab, from Millennium Pharmaceuticals, is a Biologic Drug which acts by blocking the binding between α4β7 Integrin and Mucosal Adressin Cell Adhesion Molecule-1 (MADCAM-1).

Vedolizumab is a newer version of the less specific biologic drug, Tysabri (Natalizumab), which blocked all α4 Integrins.

The more specific design of Vedolizumab is expected to have a more specific effect in the Gastrointestinal (GI) Tract.

Vedolizumab (MLN0002) Phase III Clinical Trial

Phase III Clinical Trial of Vedolizumab (MLN0002) for Crohn's Disease and Ulcerative Colitis

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease (GEMINI LTS)

One doctor has written a paper stating they feel Vedolizumab should not be approved due to side effects that are being reported in trials.


Baumgart, D. C. (2010), Veto on vedolizumab (MLN0002) for Crohn's disease. Inflamm Bowel Dis, 16: 537538. doi: 10.1002/ibd.21078

Feagan, B. G. and Parikh, A. (2010), Response to Baumgart review. Inflamm Bowel Dis, 16: 1449. doi: 10.1002/ibd.21201

Popular Threads Discussing Vedolizumab

Page Tools
No one has commented on this article.

Page Tools
Search this Page

All times are GMT -5. The time now is 07:16 PM.
Copyright 2006-2017